We serve Chemical Name:DL-LYSINE:2HCL (EPSILON-15N) CAS:204451-46-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:DL-LYSINE:2HCL (EPSILON-15N)
CAS.NO:204451-46-7
Synonyms:DL-Lysine-|A-15N dihydrochloride;Lysine-N-N, hydrochloride (1:2);MFCD00084224;(N-N)Lysine dihydrochloride
Molecular Formula:C6H16Cl2N2O2
Molecular Weight:220.103
HS Code:
Physical and Chemical Properties:
Melting point:190ºC(lit.)
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:89.34000
Exact Mass:219.055923
LogP:2.53190
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like DL-Lysine-|A-15N dihydrochloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(N-N)Lysine dihydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,DL-Lysine-|A-15N dihydrochloride Use and application,MFCD00084224 technical grade,usp/ep/jp grade.
Related News: On the basis of achieving low-cost and high-quality processes, production capacity will become the core driving force for API companies to break through sales bottlenecks. DL-LYSINE:2HCL (EPSILON-15N) manufacturer A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018. DL-LYSINE:2HCL (EPSILON-15N) supplier A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018. DL-LYSINE:2HCL (EPSILON-15N) vendor Vietnam backtracked on Saturday and narrowed its restrictions to most flights from mainland China. DL-LYSINE:2HCL (EPSILON-15N) factory A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018.
